Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Executive Briefing – China's revolution in the making

This article was originally published in Scrip

Executive Summary

An analysis of the Chinese healthcare market in 2007 highlights its many contradictions. On the one hand, it grew by an astonishing 25.5% compared with the previous year,1 surpassing growth figures for most developed countries. By the end of last year, the Chinese market was valued at Yuan633.8 billion ($86.8 billion). Yet on the other hand, China is still grappling with serious problems, such as high drug prices; poor medical insurance coverage, especially in rural Chinese and migrant populations; fake and/or unsafe drugs; and a rather complicated (and constantly changing) regulatory environment. Against this backdrop, no other industry has drawn quite as much criticism in China as healthcare.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC000327

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel